ArticleNeoplasia (New York, N.Y.)2012

Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.

Jörg Haupenthal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.